GlassScriptPhysician profile
Cathy Kreimer
NPI 1104284496
$5,913.34
in general payments reported to CMS, 2019-2025
41 companies · $967 in 2025
The $967 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,115 · 2022: $1,473 · 2023: $1,380 · 2024: $978 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,100 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,488.92 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $453.75 | 2021 | |
| Pfizer INC. | $315.83 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $303.40 | 2021-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Biohaven Pharmaceutical Holding Company LTD. | $302.51 | 2022 | |
| Lilly USA, LLC | $264.93 | 2021-2024 | Emgality |
| Amgen INC. | $230.22 | 2021-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $226.87 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Sk Life Science, INC. | $194.25 | 2021-2024 | Xcopri |
| Lundbeck LLC | $161.74 | 2021-2025 | Vyepti |
| Eisai INC. | $120.55 | 2024 | |
| Jazz Pharmaceuticals INC. | $97.14 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.44 | 2023 | Relistor |
| Janssen Biotech, INC. | $49.30 | 2025 | Tremfya |
| Axsome Therapeutics, INC. | $46.72 | 2025 | Symbravo |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Kreimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.